23andMe to Cut 40% of Its Staff Amid Grim Financials
The DNA testing kit company is also discontinuing new developments to its therapeutics program, which has been focused on using customers’ DNA data to aid in drug discovery.
23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a staggering 40 percent of its workforce. This decision, described by CEO Anne Wojcicki as “difficult but necessary,” comes as the ...
23andMe is laying off 40 percent of its staff
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs will impact 40 percent of the genetic testing company’s workforce. 23andMe CEO and co-founder Anne Wojcicki said in a statement released on Monday that the staff reduction would save the beleaguered company more than $35 million.
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to reduce overall headcount by 40% of workforce
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing
Hosted on MSN18h
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our ...
23andMe’s stock falls after company says there’s substantial doubt it can stay in business
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, shedding ...
23andMe reports sales decline day after announcing plans to cut 40% of workforce
Embattled genetic testing provider 23andMe said on Tuesday that revenue declined from a year earlier, a day after the company ...
Benzinga.com23h
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our ...
NBC Los Angeles1d
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
Yahoo Finance8h
Q2 2024 23andMe Holding Co. Earnings Call
Anne Wojcicki; Chairman of the Board, President, Chief Executive Officer, Co-Founder; 23andMe Holding Co. Joseph Selsavage; Interim Chief Financial Officer, Chief Accounting Officer; 23andMe ...
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...